Medtronic plc stock (IE00BTN1Y115): Global leader in medical technology

Medtronic plc maintains its position as one of the world's largest medical technology companies, focusing on therapies that address chronic diseases. The company reported fiscal 2026 second-quarter results on February 18, 2026, with worldwide revenue of $8.4 billion, up 5.4% as reported and 4.6% on an organic basis from the prior-year period, according to Medtronic press release as of 02/18/2026.

The stock traded at 82.35 USD on 05/13/2026 on Nasdaq, reflecting steady performance amid broader market trends in healthcare, according to Yahoo Finance as of 05/13/2026. This quarter's growth was driven by strength in cardiovascular and diabetes segments, key areas for US investors seeking defensive growth in medtech.

As of: 13.05.2026

By the editorial team – specialized in equity coverage.

Medtronic plc: core business model

Medtronic plc develops, manufactures, and sells a wide range of medical devices and therapies. Its portfolio includes pacemakers, insulin pumps, spinal cord stimulators, and surgical tools, serving over 150 countries. The company operates through four main segments: Cardiovascular, Medical Surgical, Neuroscience, and Diabetes, with the US accounting for about 48% of revenue in recent fiscal years.

This diversified model allows Medtronic to mitigate risks from any single market or therapy area. For instance, in fiscal 2025 full-year results published August 21, 2025, revenue reached $32.4 billion, up 3.6% organically, per Medtronic as of 08/21/2025. Innovation remains central, with R&D investment at approximately 8-9% of revenue annually.

Main revenue and product drivers for Medtronic plc

Cardiovascular products, including transcatheter aortic valve replacements like the Evolut platform, generated about 37% of revenue in Q2 fiscal 2026. Diabetes saw 10.1% organic growth, fueled by the MiniMed 780G system, while Neuroscience benefited from Hugo robotic-assisted surgery advancements. These drivers position Medtronic strongly in the US market, where aging demographics boost demand.

Medical Surgical portfolio, with tools for ENT and GI procedures, contributes steady growth. Overall, organic revenue growth reflects execution on pipeline launches and market share gains, as detailed in the Q2 earnings release.

Industry trends and competitive position

The global medtech market is projected to exceed $600 billion by 2026, per Statista as of 2025, driven by minimally invasive procedures and chronic disease management. Medtronic competes with Abbott, Boston Scientific, and Intuitive Surgical, holding leadership in CRM (cardiac rhythm management) and structural heart.

Its scale—over 95,000 employees—and $1.2 billion in quarterly R&D spend provide a competitive edge. US investors value this exposure to procedural growth amid healthcare spending rises.

Why Medtronic plc matters for US investors

Listed on Nasdaq as MDT, Medtronic offers US investors direct access to a global medtech giant with significant domestic revenue. About half its sales come from the US, tied to Medicare reimbursement and elective procedures, making it sensitive to US economic health and policy shifts.

Dividend yield around 3.2% as of May 2026 appeals to income-focused portfolios, with 47 consecutive years of increases. This blend of growth and yield suits long-term US equity strategies.

Conclusion

Medtronic plc demonstrates resilience through diversified revenues and innovation in high-growth medtech areas. Recent quarterly results highlight operational strength, while its US-centric exposure and dividend track record provide stability. Investors monitor upcoming fiscal Q3 results in August 2026 for continued momentum.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.